Univariate and multivariate Hazard Ratios (HRs) for cART initiation according to geographic origin, gender and HIV transmission group in baseline CD4 cell count strata (Cox model).

<p>* HR adjusted for age at enrolment, enrolment period, region of care, pVL at enrolment, and hepatitis B antigen and hepatitis C antibody status; Abbreviations: cART, Combination antiretroviral therapy; FRA, French natives; SSA, sub-Saharan Africa; NFW, non-French West Indies; OTH, Other regions of the world; MSM, Men who have sex with men.</p

Individuals selection.

<p>Abbreviations: ADE, AIDS-defining event; cART, combination antiretroviral therapy; NRTI, Nucleoside Reverse Transcriptase Inhibitor.</p

Kaplan-Meier survival estimates of first-line cART initiation by geographic origin and CD4 cell counts [/μL] at enrolment.

<p>Abbreviations: cART, combination antiretroviral therapy; FRA, French natives; SSA, sub-Saharan Africa; NFW, non-French West Indies; OTH, Other regions of the world.</p

First-line cART regimens started during follow-up, N = 8543.

<p>Data are counts (proportions).</p><p>^a Mainly PI/r + II or PI/r + NNRTI or 2 PIs/r.</p><p>^b Mainly PI/r monotherapy or 1 II + 1 PI/r or 1 PI/r + 1 NNRTI.</p><p>Abbreviations: FRA, French natives; SSA, sub-Saharan Africa; NFW, non-French West Indies; OTH, Other regions of the world; MSM, Men who have sex with men; cART, combination antiretroviral therapy; NRTI, Nucleoside Reverse Transcriptase Inhibitor; PI/r, ritonavir-boosted protease inhibitor; NNRTI, Non-nucleoside Reverse Transcriptase Inhibitor; II, Integrase inhibitor; PI, Protease Inhibitor.</p><p>First-line cART regimens started during follow-up, N = 8543.</p